Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
Algernon Pharmaceuticals announces transformative agreement to advance Ifenprodil for chronic cough treatment, strengthening financial position and focusing on broader drug development pipeline.
The agreement represents a pivotal moment for Algernon Pharmaceuticals, positioning Ifenprodil for further development in a market with significant potential. It also allows Algernon to concentrate on advancing its broader drug development pipeline, ensuring the company remains at the forefront of innovation in the pharmaceutical industry.
